Takeaway Message: In 2024, look for DePuy-Synthes to spin out poor divisions and/or product lines and to acquire brand new companies. DePuy-Synthes has $13B to play with after sale of its consumer health business, Kenvue.
The company announced the two-year restructuring in its third-quarter earnings call. It expects the changes to accelerate growth and enhance profitability, CFO Joe Wolk said.
Orthopaedics restructuring
Johnson & Johnson announced it will restructure its orthopedics business, with plans to exit less profitable markets and product lines, CFO Joe Wolk said during th...
